Why do GLP-1 therapies transform some patients—and barely move the needle in others? 🧬💉
A recent Nature study (~28,000 participants) identifies GLP1R and GIPR variants linked to both weight loss efficacy and GI side effects.
📊 Signal: modest for weight loss, stronger for tolerability
🧠 Insight: genetics + clinical factors explain ~25% variability
🚀 Implication: early steps toward precision obesity therapeutics
The future may not be "one drug fits all," but one genome, one strategy.
